NCT05939947View on ClinicalTrials.gov

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Advanced Liver FibrosisLiver Cirrhosis
Interventions
DRUG

ALE.F02

Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.

DRUG

Placebo

Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.

Trial Locations (6)

78215

American Research Corporation, San Antonio

81241

APEX GmbH, Munich

90122

Summit Clinical Research, Malacky

400006

ARENSIA Exploratory Medicine S.R.L. - Cluj-Napoca, Cluj-Napoca

011665

ARENSIA Exploratory Medicine S.R.L., Bucharest

851 05

Summit Clinical Research, Bratislava

Sponsors
All Listed Sponsors
lead

Alentis Therapeutics AG

INDUSTRY

NCT05939947 - A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis | Biotech Hunter | Biotech Hunter